FNY Investment Advisers LLC Has $225,000 Stake in MiMedx Group, Inc. (NASDAQ:MDXG)

FNY Investment Advisers LLC raised its holdings in MiMedx Group, Inc. (NASDAQ:MDXG) by 25.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,054 shares of the company’s stock after buying an additional 6,956 shares during the period. FNY Investment Advisers LLC’s holdings in MiMedx Group were worth $225,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Prelude Capital Management LLC acquired a new position in shares of MiMedx Group in the first quarter valued at $42,000. Royce & Associates LP boosted its holdings in shares of MiMedx Group by 21.2% during the first quarter. Royce & Associates LP now owns 842,000 shares of the company’s stock worth $2,871,000 after acquiring an additional 147,000 shares during the period. JPMorgan Chase & Co. grew its position in shares of MiMedx Group by 30.6% in the first quarter. JPMorgan Chase & Co. now owns 90,265 shares of the company’s stock valued at $308,000 after purchasing an additional 21,131 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of MiMedx Group by 4.7% during the first quarter. Geode Capital Management LLC now owns 2,198,537 shares of the company’s stock worth $7,497,000 after purchasing an additional 98,900 shares during the period. Finally, Altium Capital Management LP acquired a new stake in MiMedx Group during the 1st quarter worth approximately $2,551,000. 43.85% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Stock Performance

Shares of MiMedx Group stock traded down $0.16 on Friday, reaching $7.54. 2,358,651 shares of the stock were exchanged, compared to its average volume of 506,319. The firm’s 50 day moving average is $7.49 and its 200-day moving average is $5.76. The firm has a market cap of $875.47 million, a PE ratio of -44.35 and a beta of 1.61. MiMedx Group, Inc. has a one year low of $2.43 and a one year high of $8.60.

Analyst Ratings Changes

Several research analysts have weighed in on the company. TheStreet upgraded MiMedx Group from a “d” rating to a “c-” rating in a research report on Wednesday, August 2nd. Mizuho boosted their price objective on shares of MiMedx Group from $12.00 to $14.00 in a report on Wednesday, August 9th. StockNews.com began coverage on shares of MiMedx Group in a report on Thursday, August 17th. They set a “strong-buy” rating on the stock. Finally, HC Wainwright increased their price target on MiMedx Group from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, August 2nd.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.